

Antananarivo, 22 August 2025



To
Dr. Henning Gädeke, Chair of the EDCTP Association Board and the Global Health EDCTP3

C/O

Dr. Michael Makanga, Executive Director of the Global Health EDCTP3 Joint Undertaking Global Health EDCTP3 Joint Undertaking

56 – 60 Avenue de la Toison d'Or, 1060 Brussels Belgium

Object: Endorsement letter to Support the TESA-VI program from the Institut Pasteur de Madagascar

Dear Sir/Madam,

On behalf of the Institut Pasteur de Madagascar, I would like to endorse our involvement for the TESA-VI application.

The Institut Pasteur de Madagascar (IPM) was established in 1898 and has four specific focuses that are Research, Public health, Services and Training. The IPM has a mission to contribute to the prevention and treatment of diseases and to the economic development of Madagascar through research, training and public health activities.

Most of the research Units at IPM are hosting the National Reference Laboratory and Centres for Madagascar (11/12 NRL Centres are based at IPM) recognized for their capacities in diagnosis and surveillance for infectious diseases of local and regional interest (plague, arboviruses and haemorrhagic fevers, influenza, rabies, poliomyelitis, measles, and antibiotic resistance.) and some of which are also recognized by the World Health Organization (WHO). Due to these capacities, IPM is currently a national and regional active partner of the public health and surveillance network in the Indian Ocean region that can be scaled-up to the Southern and Eastern region through the TESA network.

Dr Voahangy RASOLOFO
Scientific Director
vrasolof@pasteur.mg
BP 1274
Antananarivo 101
Téléphone : 261 20 97 401 64

The IPM will design a clinical study evaluating the WHO recommendations of TB elimination in Madagascar urban/rural areas. The study will be used as a conduit for training study personnel in conducting clinical trials and pandemic preparedness. The design of the study meets some of the main objectives of Global Health EDCTP3 and falls under Work Package 4 and 5 of the Consortium applications.

The study will be conducted in collaboration with the Malagasy Ministry of Public Health. This collaboration is critical as any findings from the study which may influence national policy change can be expeditiously implemented nationwide.

We would like to confirm our financial support which will be made up of in-kind support in the budget proposed by our institution as detailed in the Table below.

Category	Cost (€)	Justification
Human Ressources	489,675.29	70% of the salary of 01 local coordinator, 01 Clinical Research Coordinator, 01 field activities coordinator, 02 scientists, 02 engineers and 20% of PhD Students (02) and lab technologists (02) engaged in the consortium over a period of 4 years
Equipment	90,160.00	Immunology and FlowCytometry platforms, Sequencing technologies and PCR Thermocyclers Platforms (acquisition costs).
Equipment	35,592.00	Flow hoods for processing of study biological specimens, fridges, generator for electricity back-up of the clinic laboratory and the dedicated rooms.
Other goods, works and services	40,000.00	Data management centre for study participants data entry, cleaning and analysis, Biobank for storage of left over study specimens for future studies and laboratories for study and fuel for the generator and the dedicated laboratories.
Other goods, works and services	40,000.00	Dedicated laboratory for running study participants biological tests, including Biosafety Level 3 and 2 Lab access.
Other goods, works and services	23,813.71	Customs duty free certificate for importation of equipment, reagents and consumables from outside Madagascar.
	719,241	

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.


2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.

3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.

4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.

5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Sincerely,

A handwritten signature in black ink, appearing to read 'Raz', with a long horizontal stroke extending to the left.

Voahangy RASOLOFO
Scientific Director